About KOMZIFTI™ KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation ...
Artificial intelligence-enabled electrocardiography from scientific research to clinical application
Recent advancements in artificial intelligence (AI) have revolutionized the application of electrocardiography (ECG) in ...
Bristol Myers Squibb today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback